Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ)
CNY 52.41
(-0.27%)
CNY 52.41
(-0.27%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 645.03 Million CNY | 4.87% |
| 2022 | 615.05 Million CNY | 17.49% |
| 2021 | 523.5 Million CNY | 4.39% |
| 2020 | 501.48 Million CNY | 57.24% |
| 2019 | 318.92 Million CNY | 16.17% |
| 2018 | 274.52 Million CNY | 9.81% |
| 2017 | 250 Million CNY | 34.59% |
| 2016 | 185.74 Million CNY | 48.66% |
| 2015 | 124.94 Million CNY | -7.39% |
| 2014 | 134.91 Million CNY | -16.78% |
| 2013 | 162.12 Million CNY | 149.68% |
| 2012 | 64.93 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 610.45 Million CNY | -5.36% |
| 2024 Q3 | 717.12 Million CNY | 7.87% |
| 2024 Q2 | 664.77 Million CNY | 8.9% |
| 2023 Q4 | 645.03 Million CNY | 4.11% |
| 2023 Q3 | 619.53 Million CNY | 2.86% |
| 2023 Q2 | 602.33 Million CNY | 19.71% |
| 2023 FY | 645.03 Million CNY | 4.87% |
| 2023 Q1 | 503.17 Million CNY | -18.19% |
| 2022 Q3 | 544.63 Million CNY | 2.56% |
| 2022 Q2 | 531.01 Million CNY | 15.21% |
| 2022 FY | 615.05 Million CNY | 17.49% |
| 2022 Q1 | 460.92 Million CNY | -11.95% |
| 2022 Q4 | 615.05 Million CNY | 12.93% |
| 2021 Q1 | 459.64 Million CNY | -8.34% |
| 2021 Q2 | 435.1 Million CNY | -5.34% |
| 2021 Q3 | 421.6 Million CNY | -3.1% |
| 2021 Q4 | 523.5 Million CNY | 24.17% |
| 2021 FY | 523.5 Million CNY | 4.39% |
| 2020 FY | 501.48 Million CNY | 57.24% |
| 2020 Q2 | 422.52 Million CNY | 56.14% |
| 2020 Q3 | 501.98 Million CNY | 18.81% |
| 2020 Q4 | 501.48 Million CNY | -0.1% |
| 2020 Q1 | 270.61 Million CNY | -15.15% |
| 2019 FY | 318.92 Million CNY | 16.17% |
| 2019 Q1 | - CNY | 0.0% |
| 2019 Q4 | 318.92 Million CNY | 0.0% |
| 2018 FY | 274.52 Million CNY | 9.81% |
| 2017 Q4 | 250 Million CNY | 0.0% |
| 2017 FY | 250 Million CNY | 34.59% |
| 2017 Q2 | 144.94 Million CNY | 0.0% |
| 2016 Q2 | 106.79 Million CNY | 0.0% |
| 2016 Q1 | 106.79 Million CNY | -14.53% |
| 2016 FY | 185.74 Million CNY | 48.66% |
| 2016 Q3 | 159.1 Million CNY | 48.99% |
| 2016 Q4 | 159.1 Million CNY | 0.0% |
| 2015 Q1 | 95.17 Million CNY | -29.46% |
| 2015 FY | 124.94 Million CNY | -7.39% |
| 2015 Q4 | 124.94 Million CNY | 16.34% |
| 2015 Q3 | 107.39 Million CNY | -12.99% |
| 2015 Q2 | 123.43 Million CNY | 29.68% |
| 2014 Q2 | 105.04 Million CNY | 32.48% |
| 2014 Q3 | 111.66 Million CNY | 6.31% |
| 2014 Q1 | 79.29 Million CNY | -51.09% |
| 2014 Q4 | 134.91 Million CNY | 20.82% |
| 2014 FY | 134.91 Million CNY | -16.78% |
| 2013 FY | 162.12 Million CNY | 149.68% |
| 2013 Q1 | - CNY | 0.0% |
| 2013 Q4 | 162.12 Million CNY | 0.0% |
| 2013 Q3 | 162.12 Million CNY | 0.0% |
| 2012 FY | 64.93 Million CNY | 0.0% |